{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Vital signs included body temperature, body weight, blood pressure and heart rate.","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg, injection, intravenously, every 3 weeks on Day 1 of each 21-day treatment cycle up to a maximum of 16 brentuximab vedotin doses.","id":"OG000","title":"Brentuximab Vedotin"},{"description":"Brentuximab vedotin 1.8 mg/kg, injection, intravenously, every 3 weeks on Day 1 of each 21-day treatment cycle up to a maximum of 16 brentuximab vedotin doses and rifampicin, 600 mg, capsules, orally, once daily from Day 1 of treatment Cycle 0 through Day 21 of treatment cycle 3.","id":"OG001","title":"Brentuximab Vedotin + Rifampicin"}],"paramType":"NUMBER","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline up to 30 days after last dose of study drug (30 Days after Cycle 16)","title":"Number of Participants With Clinically Significant Change From Baseline in Vital Signs","type":"SECONDARY","unitOfMeasure":"participants"}